logo

Lipocine Inc (LPCN)



Trade LPCN now with
  Date
  Headline
8/7/2019 8:08:40 AM Lipocine Q2 Net Loss $3.4 Mln Or $0.14/shr Vs. Net Loss Of $3.3 Mln Or $0.15/shr Prior Year
7/23/2019 8:04:23 AM Lipocine Gets FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population
5/8/2019 8:04:41 AM Lipocine Q1 Net Loss $3.2 Mln Or $0.14/shr Vs Net Loss Of $2.7 Mln Or $0.13/shr Prior Year
3/14/2019 8:07:50 AM Lipocine Announces Presentation Highlighting Therapeutic Potential Of LPCN 1144 In NAFLD And NASH Selected For ENDO 2019
3/12/2019 8:06:39 AM Lipocine Announces Top-line Results From 16-week Liver Fat Imaging Study With LPCN 1144
1/24/2019 8:08:42 AM Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
1/14/2019 8:17:06 AM Lipocine Says USPTO Grants Priority Motion To Company And Enters Judgment Against Clarus
12/31/2018 8:01:02 AM Lipocine Announces Completion Of Phlebotomy Study
12/21/2018 8:02:33 AM Lipocine Announces LPCN 1144 Clinical Trial Results Selected For Presentation
12/21/2018 8:01:58 AM Lipocine Announces LPCN 1144 Clinical Trial Results Selected For Presentation At 2019 NASH-TAG Conference
10/11/2018 8:06:39 AM Lipocine Reports LPCN 1144 Clinical Trial Results Selected For Late-Breaker Presentation At The Liver Meeting 2018
8/7/2018 7:45:23 AM Lipocine Q2 Net Loss $3.3 Mln Or $0.15/Shr Vs Loss Of $6.1 Mln Or $0.31/Shr Last Year
6/7/2018 8:10:14 AM Lipocine Announces Dosing In Ambulatory Blood Pressure Study For TLANDO
5/9/2018 7:00:31 AM Lipocine Receives Complete Response Letter From FDA For TLANDO
5/7/2018 8:12:17 AM Lipocine Q1 Net Loss Of $2.7 Mln Or $0.13/shr Vs. Net Loss Of $4.9 Mln Or $0.26/shr Prior Year